Published in J Biol Chem on March 25, 1992
Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci U S A (1994) 2.18
The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function. Ann Rheum Dis (2000) 0.91
Identification of amino acid residues important for ligand binding to Fas. J Exp Med (1997) 0.89
Tag7 (PGLYRP1) in Complex with Hsp70 Induces Alternative Cytotoxic Processes in Tumor Cells via TNFR1 Receptor. J Biol Chem (2015) 0.81
Inhibition of interferon-gamma by an interferon-gamma receptor immunoadhesin. Immunology (1993) 0.81
Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells. J Biol Chem (2015) 0.80
Soluble FasR ligand-binding domain: high-yield production of active fusion and non-fusion recombinant proteins using the baculovirus/insect cell system. Biochem J (1998) 0.75
Quorum-sensing in Gram-negative bacteria. FEMS Microbiol Rev (2001) 6.93
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 6.82
Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem (1996) 6.22
Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ (2003) 3.66
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol (1989) 3.62
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem (1994) 3.46
Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity (2000) 3.45
Primary structure and biochemical properties of an M2 muscarinic receptor. Science (1987) 3.16
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature (1998) 2.98
Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol (2000) 2.78
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med (2001) 2.66
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol (1999) 2.66
New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene (2010) 2.56
Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell (1999) 2.42
Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem (2001) 2.40
Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J (1987) 2.39
Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J Biol Chem (1997) 2.33
A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol (1997) 2.31
Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol (2000) 2.29
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature (1988) 2.03
Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis. Proc Natl Acad Sci U S A (1990) 1.99
TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol (2001) 1.92
Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. Science (1995) 1.90
Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol (1993) 1.89
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 1.88
The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA. J Immunol (1990) 1.83
Monoclonal antibody (B27M2) subdividing HLA-B27. Hum Immunol (1982) 1.81
The MHC-binding and gp120-binding functions of CD4 are separable. Science (1989) 1.77
Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol (1996) 1.72
Humanization of an antibody directed against IgE. J Immunol (1993) 1.64
Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR. Curr Biol (1999) 1.63
Recombinant tumor necrosis factor causes activation of human granulocytes. Blood (1987) 1.62
Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ (2008) 1.61
Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res (2001) 1.58
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene (2007) 1.57
Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol (1991) 1.57
A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol (1998) 1.53
High resolution functional analysis of antibody-antigen interactions. J Mol Biol (1992) 1.49
Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol (2001) 1.46
The syndrome of neonatal copper deficiency. Pediatrics (1973) 1.45
Functional characterization of the Bcl-2 gene family in the zebrafish. Cell Death Differ (2006) 1.43
Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer (1990) 1.36
A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry (2000) 1.34
Identification of a ligand for the death-domain-containing receptor Apo3. Curr Biol (1998) 1.34
Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun (1999) 1.33
Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol (1996) 1.33
APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett (1998) 1.32
Ligand-induced assembly and activation of the gamma interferon receptor in intact cells. Mol Cell Biol (1996) 1.32
Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci U S A (1991) 1.29
Mammalian cell transient expression of tissue factor for the production of antigen. Protein Eng (1990) 1.28
A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors. Nature (1992) 1.26
Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res (1996) 1.25
Cloning and expression of a human CDC42 GTPase-activating protein reveals a functional SH3-binding domain. J Biol Chem (1993) 1.20
A truncated intracellular HER2/neu receptor produced by alternative RNA processing affects growth of human carcinoma cells. Mol Cell Biol (1993) 1.20
Evidence for an autocrine role of activin B within rat anterior pituitary cultures. Endocrinology (1991) 1.19
Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1. J Virol (1993) 1.16
Iron treatment in children with attention deficit hyperactivity disorder. A preliminary report. Neuropsychobiology (1997) 1.14
Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul (1991) 1.13
Monoclonal antibodies to the extracellular domain of HIV-1IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates. AIDS Res Hum Retroviruses (1992) 1.11
Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res (2001) 1.10
TGF-beta: a possible autocrine immune regulator. Ciba Found Symp (1991) 1.09
Delineation of the cell-extrinsic apoptosis pathway in the zebrafish. Cell Death Differ (2006) 1.09
Histocompatibility determinants in Israeli Jewish patients with coeliac disease: population and family study. Tissue Antigens (1981) 1.08
Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand J Immunol (2000) 1.07
Characterization of the human 5-hydroxytryptamine1B receptor. J Biol Chem (1992) 1.06
Comparison of dynamic (brush) and static (pressure) mechanical allodynia in migraine. Cephalalgia (2006) 1.04
Enzymatic cleavage of a CD4 immunoadhesin generates crystallizable, biologically active Fd-like fragments. Biochemistry (1990) 1.02
Molecular cloning and expression of the murine RANTES cytokine: structural and functional conservation between mouse and man. Eur J Immunol (1992) 1.02
Coeliac activity of the gliadin peptides CT-1 and CT-2. Z Lebensm Unters Forsch (1986) 1.00
Interferon gamma signals via a high-affinity multisubunit receptor complex that contains two types of polypeptide chain. Proc Natl Acad Sci U S A (1995) 0.99
Biochemical properties of the 75-kDa tumor necrosis factor receptor. Characterization of ligand binding, internalization, and receptor phosphorylation. J Biol Chem (1992) 0.98
Immunological assay for the diagnosis of coeliac disease: interaction between purified gluten fractions. Pediatr Res (1980) 0.96
Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D. J Immunol (1999) 0.95
HLA-DR epitope region definition by use of monoclonal antibody probes. J Immunol (1980) 0.95
Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cell-mediated cytotoxicity. Cytokine (1999) 0.95
A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann Neurol (1998) 0.95
Niemann-Pick disease and giant cell transformation of the liver. Acta Paediatr Scand (1971) 0.94
Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J Immunol (1996) 0.94
Mutational analysis of thrombopoietin for identification of receptor and neutralizing antibody sites. J Biol Chem (1997) 0.93
Celiac disease among Ashkenazi Jews from Israel. A study of the HLA class II alleles and their associations with disease susceptibility. Hum Immunol (1993) 0.93
Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor. Biochemistry (1993) 0.93
Immunoadhesins: principles and applications. Trends Biotechnol (1996) 0.93
Nocturnal acute laryngospasm in children: a possible epileptic phenomenon. J Child Neurol (2000) 0.92
An in-vitro immunological assay for diagnosis of coeliac disease. Lancet (1978) 0.92
Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. J Clin Invest (1995) 0.91
Amino-acid sequence of the coeliac active gliadin peptide B 3142. Z Lebensm Unters Forsch (1984) 0.90
Natriuretic peptide receptor-B (guanylyl cyclase-B) mediates C-type natriuretic peptide relaxation of precontracted rat aorta. J Biol Chem (1995) 0.90
Effect of splenectomy on destructive bone changes in children with chronic (Type I) Gaucher disease. Eur J Pediatr (1986) 0.89
Structural basis of muscarinic acetylcholine receptor subtype diversity. Trends Pharmacol Sci (1988) 0.87
Human natriuretic peptide receptor-A guanylyl cyclase. Hormone cross-linking and antibody reactivity distinguish receptor glycoforms. J Biol Chem (1992) 0.87
Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice. Gene Ther (2006) 0.87
Functional diversity of muscarinic receptor subtypes in cellular signal transduction and growth. Trends Pharmacol Sci (1989) 0.86
Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1. Cancer Res (2000) 0.85
HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies. J Clin Pathol (1992) 0.85
Determination of residues involved in ligand binding and signal transmission in the human IFN-alpha receptor 2. J Immunol (1999) 0.85
Inhibition of murine erythroid colony formation in vitro by interferon gamma and correction by interferon receptor immunoadhesin. Blood (1994) 0.85